Deep Brain Stimulation and Cognitive Outcomes Among Patients With Parkinson's Disease: A Historical Cohort Study.


Journal

The Journal of neuropsychiatry and clinical neurosciences
ISSN: 1545-7222
Titre abrégé: J Neuropsychiatry Clin Neurosci
Pays: United States
ID NLM: 8911344

Informations de publication

Date de publication:
2019
Historique:
pubmed: 23 2 2019
medline: 17 3 2020
entrez: 23 2 2019
Statut: ppublish

Résumé

Deep brain stimulation (DBS) is an effective treatment for motor symptoms of Parkinson's disease; however, there is conflicting literature about the effect of DBS on cognitive function. The authors conducted a historical cohort study involving patients with Parkinson's disease who underwent DBS of the globus pallidus pars interna (GPi; N=12) or subthalamic nucleus (STN; N=17). The authors investigated differences in four neuropsychological test scores at 6 months post-DBS (follow-up) as compared with baseline (i.e., Boston Naming Test, WAIS Verbal Comprehension Index [WAIS-VCI], Working Memory Index [WAIS-WMI], and Processing Speed Index [WAIS-PSI]). GPi DBS patients showed no difference between baseline and follow-up on any neuropsychological test. STN DBS patients had lower scores indicating decreased performance at follow-up as compared with baseline on WAIS-PSI (mean [SD], 91.47 [10.42] versus 81.65 [12.03]; p=0.03). There was a significant (p=0.008) difference between the change in baseline to follow-up scores on the WAIS-VCI for the STN DBS and GPi DBS groups (i.e., STN DBS patients scored lower at the 6-month follow-up compared with baseline, whereas GPi DBS patients scored higher). GPi may be a preferred target for DBS in patients with Parkinson's disease when considering cognitive outcomes.

Identifiants

pubmed: 30791806
doi: 10.1176/appi.neuropsych.18050118
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

196-200

Subventions

Organisme : NIA NIH HHS
ID : R01 AG057708
Pays : United States

Auteurs

Allison L Hansen (AL)

The Translational Neuroscience and Aging Laboratory, Mayo Clinic, Phoenix, Ariz. (Krell-Roesch, Velgos, Geda); the Department of Psychiatry and Psychology, Mayo Clinic, Phoenix, Ariz. (Kirlin, Geda); the Department of Neurological Surgery, Phoenix, Ariz. (Lyons); and the Department of Neurology, Mayo Clinic, Phoenix, Ariz. (Geda, Mehta).

Janina Krell-Roesch (J)

The Translational Neuroscience and Aging Laboratory, Mayo Clinic, Phoenix, Ariz. (Krell-Roesch, Velgos, Geda); the Department of Psychiatry and Psychology, Mayo Clinic, Phoenix, Ariz. (Kirlin, Geda); the Department of Neurological Surgery, Phoenix, Ariz. (Lyons); and the Department of Neurology, Mayo Clinic, Phoenix, Ariz. (Geda, Mehta).

Kristin A Kirlin (KA)

The Translational Neuroscience and Aging Laboratory, Mayo Clinic, Phoenix, Ariz. (Krell-Roesch, Velgos, Geda); the Department of Psychiatry and Psychology, Mayo Clinic, Phoenix, Ariz. (Kirlin, Geda); the Department of Neurological Surgery, Phoenix, Ariz. (Lyons); and the Department of Neurology, Mayo Clinic, Phoenix, Ariz. (Geda, Mehta).

Martin M Limback-Stokin (MM)

The Translational Neuroscience and Aging Laboratory, Mayo Clinic, Phoenix, Ariz. (Krell-Roesch, Velgos, Geda); the Department of Psychiatry and Psychology, Mayo Clinic, Phoenix, Ariz. (Kirlin, Geda); the Department of Neurological Surgery, Phoenix, Ariz. (Lyons); and the Department of Neurology, Mayo Clinic, Phoenix, Ariz. (Geda, Mehta).

Kimberly Roesler (K)

The Translational Neuroscience and Aging Laboratory, Mayo Clinic, Phoenix, Ariz. (Krell-Roesch, Velgos, Geda); the Department of Psychiatry and Psychology, Mayo Clinic, Phoenix, Ariz. (Kirlin, Geda); the Department of Neurological Surgery, Phoenix, Ariz. (Lyons); and the Department of Neurology, Mayo Clinic, Phoenix, Ariz. (Geda, Mehta).

Stefanie N Velgos (SN)

The Translational Neuroscience and Aging Laboratory, Mayo Clinic, Phoenix, Ariz. (Krell-Roesch, Velgos, Geda); the Department of Psychiatry and Psychology, Mayo Clinic, Phoenix, Ariz. (Kirlin, Geda); the Department of Neurological Surgery, Phoenix, Ariz. (Lyons); and the Department of Neurology, Mayo Clinic, Phoenix, Ariz. (Geda, Mehta).

Mark K Lyons (MK)

The Translational Neuroscience and Aging Laboratory, Mayo Clinic, Phoenix, Ariz. (Krell-Roesch, Velgos, Geda); the Department of Psychiatry and Psychology, Mayo Clinic, Phoenix, Ariz. (Kirlin, Geda); the Department of Neurological Surgery, Phoenix, Ariz. (Lyons); and the Department of Neurology, Mayo Clinic, Phoenix, Ariz. (Geda, Mehta).

Yonas E Geda (YE)

The Translational Neuroscience and Aging Laboratory, Mayo Clinic, Phoenix, Ariz. (Krell-Roesch, Velgos, Geda); the Department of Psychiatry and Psychology, Mayo Clinic, Phoenix, Ariz. (Kirlin, Geda); the Department of Neurological Surgery, Phoenix, Ariz. (Lyons); and the Department of Neurology, Mayo Clinic, Phoenix, Ariz. (Geda, Mehta).

Shyamal H Mehta (SH)

The Translational Neuroscience and Aging Laboratory, Mayo Clinic, Phoenix, Ariz. (Krell-Roesch, Velgos, Geda); the Department of Psychiatry and Psychology, Mayo Clinic, Phoenix, Ariz. (Kirlin, Geda); the Department of Neurological Surgery, Phoenix, Ariz. (Lyons); and the Department of Neurology, Mayo Clinic, Phoenix, Ariz. (Geda, Mehta).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH